BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/30/2021 8:56:50 AM | Browse: 652 | Download: 1787
 |
Received |
|
2020-10-27 03:07 |
|
Peer-Review Started |
|
2020-10-22 00:43 |
|
First Decision by Editorial Office Director |
|
2020-12-13 20:04 |
|
Return for Revision |
|
2020-12-13 20:04 |
|
Revised |
|
2020-12-26 03:16 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-02-04 08:04 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-02-04 19:06 |
|
Articles in Press |
|
2021-02-04 19:06 |
|
Edit the Manuscript by Language Editor |
|
2021-02-09 00:55 |
|
Typeset the Manuscript |
|
2021-03-21 09:29 |
|
Publish the Manuscript Online |
|
2021-03-30 08:56 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Case Report |
| Article Title |
Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jing-Tao Gao, Li Xie, Li-Ping Ma, Wei Shu, Li-Jie Zhang, Yu-Jia Ning, Shi-Heng Xie, Yu-Hong Liu and Meng-Qiu Gao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Meng-Qiu Gao, MD, PhD, Director, Director, Doctor, Doctor, Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9 Beiguan Street, Tongzhou District, Beijing 101149, China. gaomengqiu@bjxkyy.cn |
| Key Words |
Pulmonary tuberculosis; Bedaquiline; Extensively drug-resistant tuberculosis; Case report; Tuberculosis |
| Core Tip |
Bedaquiline is among the prioritized drugs recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis (XDR-TB). Many patients cannot achieve better clinical improvement after bedaquiline is stopped at 24-wk. However, there is no recommendation or guideline on bedaquiline administration beyond 24 wk, which is an important consideration when balancing the benefit of prognosis for XDR-TB against the uncertain safety concerning the newer antibiotics. In the two patients reported here, the longer regimen, including 36-wk bedaquiline treatment, might be an option for patients with XDR-TB. More studies are needed on exploring the effectiveness and safety of prolonged use of bedaquiline for 36 wk vs standard 24 wk in the treatment of multidrug-resistant/XDR-TB, or further exploring the biomarker and criteria indicative for extension of bedaquline to facilitate clinical use of this novel drug. |
| Publish Date |
2021-03-30 08:56 |
| Citation |
Gao JT, Xie L, Ma LP, Shu W, Zhang LJ, Ning YJ, Xie SH, Liu YH, Gao MQ. Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports. World J Clin Cases 2021; 9(10): 2326-2333 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i10/2326.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i10.2326 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
